ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1681

Supernatants from Activated Macrophages Contain Citrullinated Vimentin and Induce Extracellular Matrix Deposition from Fibroblasts

nozima Aripova1, Michael Duryee1, Eric Daubach1, carlos hunter1, Bryant England1, James O'Dell1, Ted Mikuls2 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2022

Keywords: autoantigens, citrullination, Fibroblasts, Synovial, Inflammation, macrophages

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Innate Immunity Poster: Basic and Translational Science

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Studies have shown that activated macrophages secrete several factors that promote human fibroblast-like synoviocyte (HFLS) activation, resulting in an invasive phenotype, that contributes to extracellular matrix deposition and remodeling in the synovium of patients with rheumatoid arthritis (RA). We have previously shown that the modification of proteins with malondialdehyde-acetaldehyde (MAA) and/or citrulline are able to directly stimulate macrophages to initiate pro-inflammatory and profibrotic responses. However, it is unknown whether stimulated macrophages release factors that could affect HFLS function. Therefore, the purpose of this study was to evaluate whether MAA-modified and/or citrullinated fibrinogen is capable of stimulating macrophages to release factor(s) that activate HFLS and alter the deposition of extracellular matrix proteins.

Methods: Phorbol 12-myristate 13-acetate (PMA)-treated U937 cells were stimulated with MAA, citrulline (CIT), or MAA-citrulline (MAA-CIT) modified fibrinogen (FIB). U937 cell lysates were evaluated for citrullinated proteins, vimentin, and β-actin expression using Western Blot. HFLS from RA synovium (HFLS-RA) were incubated with U937 stimulated supernatants, or directly with the modified fibrinogen antigens. HFLS-RA cells were assessed for extracellular matrix deposition markers using fluorescent immunohistochemistry (IHC) and Western Blotting.

Results: Western Blots of U937 cells stimulated with FIB-MAA-CIT demonstrated increased citrullination (p< 0.001 vs. others) but no change in the expression of vimentin (57 kDa) (Fig. 1). Treatment of U937 cells with FIB-CIT led to a slight increase in both vimentin expression (p< 0.05) and citrullination of the same protein band (p< 0.05 vs. unmodified FIB). By IHC, exposure of HFLS-RA to U937 supernatants, collected following stimulation with FIB-CIT or FIB-MAA-CIT, demonstrated an elongated and round, “spindle-shaped” fibroblast morphology suggesting HFLS activation (Fig. 2A) and increased expression of vimentin (Fig. 2B, p< 0.001) and type II collagen (Fig. 2C, p< 0.001) as compared to direct HFLS stimulation. Similar results were observed by Western Blot wherein protein expression of vimentin was increased when HFLS-RA cells were incubated with U937 cell supernatants following stimulation with FIB-CIT (p< 0.001) or FIB-MAA-CIT (p< 0.001) in comparison to direct antigen stimulation (Fig.3D,E). In contrast, U937 supernatants from FIB-MAA treatment significantly increased HFLS-RA cellular deposition of type II collagen (p< 0.001) compared to direct stimulation with the same modification, but yielded less striking changes in cellular morphology (Fig. 3A,C).

Conclusion: These findings suggest that exposure to protein antigens modified with MAA and/or citrulline result in the release of citrullinated vimentin from macrophages. Furthermore, supernatants of activated macrophages induce HFLS secretion and deposition of extracellular matrices that likely contribute to the fibrotic responses observed in RA pathogenesis. Whether the HLFS activation observed is due to citrullinated vimentin, as has been demonstrated by other groups, warrants additional study.

Supporting image 1

Figure 1. Western Blot from Stimulated U937 Cells. U937 cells were stimulated with modified fibrinogen antigens. CIT: citrullination, FIB: fibrinogen, FIB-MAA: fibrinogen-MAA, FIB-CIT: fibrinogen-citrulline, FIB-MAA-CIT: fibrinogen-MAA-citrulline. Cell lysates were probed with (A) anti-citrulline, anti-vimentin, and anti-β-actin antibodies. Densitometry of normalized values to β-actin of (B) ~57 kDa citrullination band for CIT, and for (C) vimentin. All the values were compared to unmodified FIB (*p<0.001, #p<0.05) and between the groups (***p<0.001, **p<0.05), n=3.

Supporting image 2

Figure 2. Fluorescent IHC and Western Blot Experiments from HFLS-RA cells. HFLS-RA cells were stimulated with either supernatants from U937 cells or directly stimulated with modified fibrinogen antigens. U937 cell supernatants were collected after stimulation with modified fibrinogen antigens. FIB: fibrinogen, FIB-MAA: fibrinogen-MAA, FIB-CIT: fibrinogen-citrulline, FIB-MAA-CIT: fibrinogen-MAA-citrulline, Type II COL: type II collagen. (A) Images of HFLS-RA cells and Mean Pixel Density (MPD) measurements of (B) vimentin, and (C) type II collagen. (D) Blots of HFLS-RA cells probed with anti-vimentin and anti-β-actin antibody. (E) Quantification of blots for vimentin protein expression. All values were compared to unmodified FIB (*p<0.001, #p<0.05) and between the stimulation groups (***p<0.001, **p<0.05). N=8 for fluorescent microscopy experiment (A-C) and n=3 for Western Blot experiment (D-E).


Disclosures: n. Aripova, None; M. Duryee, None; E. Daubach, None; c. hunter, None; B. England, Boehringer-Ingelheim; J. O'Dell, None; T. Mikuls, Gilead Sciences, Bristol-Myers Squibb, Horizon, Sanofi, Pfizer Inc; G. Thiele, None.

To cite this abstract in AMA style:

Aripova n, Duryee M, Daubach E, hunter c, England B, O'Dell J, Mikuls T, Thiele G. Supernatants from Activated Macrophages Contain Citrullinated Vimentin and Induce Extracellular Matrix Deposition from Fibroblasts [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/supernatants-from-activated-macrophages-contain-citrullinated-vimentin-and-induce-extracellular-matrix-deposition-from-fibroblasts/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/supernatants-from-activated-macrophages-contain-citrullinated-vimentin-and-induce-extracellular-matrix-deposition-from-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology